JP2002533336A - 三環式ファルネシルタンパク質トランスフェラーゼインヒビター - Google Patents

三環式ファルネシルタンパク質トランスフェラーゼインヒビター

Info

Publication number
JP2002533336A
JP2002533336A JP2000589531A JP2000589531A JP2002533336A JP 2002533336 A JP2002533336 A JP 2002533336A JP 2000589531 A JP2000589531 A JP 2000589531A JP 2000589531 A JP2000589531 A JP 2000589531A JP 2002533336 A JP2002533336 A JP 2002533336A
Authority
JP
Japan
Prior art keywords
alkyl
substituted
aryl
arylalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000589531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002533336A5 (enExample
Inventor
アーサー ジー． タベラス，
ロナルド ジェイ． ドール，
アラン ビー． クーパー，
ジョアン エイ． フェレイラ，
ティモシー グジ，
アラン ケイ． マラムス，
ディナナス エフ． レーン，
ビョア エム． ジリヤバラバン，
アドリアーノ アフォンソ，
シンシア ジェイ． アキ，
ジャンピング チャオ，
カーメン アルバレス，
ジョゼフ エム． ケリー，
タリク ラルワニ，
ジャグディッシュ エイ． デサイ，
ジェイムズ ジェイ． エス． ワン，
ジェイ ウェインステイン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2002533336A publication Critical patent/JP2002533336A/ja
Publication of JP2002533336A5 publication Critical patent/JP2002533336A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000589531A 1998-12-18 1999-12-16 三環式ファルネシルタンパク質トランスフェラーゼインヒビター Pending JP2002533336A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18
US09/216,398 1998-12-18
PCT/US1999/027939 WO2000037459A1 (en) 1998-12-18 1999-12-16 Tricyclic farnesyl protein transferase inhibitors

Publications (2)

Publication Number Publication Date
JP2002533336A true JP2002533336A (ja) 2002-10-08
JP2002533336A5 JP2002533336A5 (enExample) 2007-02-08

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000589531A Pending JP2002533336A (ja) 1998-12-18 1999-12-16 三環式ファルネシルタンパク質トランスフェラーゼインヒビター

Country Status (20)

Country Link
EP (1) EP1140902A1 (enExample)
JP (1) JP2002533336A (enExample)
KR (1) KR20010081116A (enExample)
CN (1) CN1326850C (enExample)
AR (1) AR021718A1 (enExample)
AU (1) AU776558B2 (enExample)
BR (1) BR9916314A (enExample)
CA (1) CA2354779A1 (enExample)
CO (1) CO5160350A1 (enExample)
CZ (1) CZ20011950A3 (enExample)
HU (1) HUP0202152A2 (enExample)
IL (1) IL143408A0 (enExample)
NO (1) NO20012961L (enExample)
NZ (1) NZ511878A (enExample)
PE (1) PE20001342A1 (enExample)
PL (1) PL348293A1 (enExample)
SK (1) SK7592001A3 (enExample)
TR (1) TR200101755T2 (enExample)
WO (1) WO2000037459A1 (enExample)
ZA (1) ZA200104233B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523104A (ja) * 2004-12-13 2008-07-03 シェーリング コーポレイション 癌を治療するための新規なファルネシルタンパク質トランスフェラーゼ阻害剤およびその使用
JP2008523148A (ja) * 2004-12-14 2008-07-03 シェーリング コーポレイション ファルネシルプロテイントランスフェラーゼインヒビターおよび増殖性疾患を処置するための方法
JP2017512780A (ja) * 2014-03-19 2017-05-25 ヴィアメット ファーマスーティカルズ，インコーポレイテッド ２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−置換ピリジン−２−イル）−３−（１ｈ−テトラゾール−１−イル）プロパン−２−オールおよびその調製工程
US10301283B2 (en) 2014-03-19 2019-05-28 Dow Agrosciences, Llc 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510760A (ja) * 1993-10-15 1996-11-12 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式アミドおよび三環式尿素化合物
JPH10511980A (ja) * 1995-04-07 1998-11-17 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの阻害に有用な三環式化合物
JPH10511981A (ja) * 1995-04-07 1998-11-17 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の処置に有用な三環式化合物
WO1998057960A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510760A (ja) * 1993-10-15 1996-11-12 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式アミドおよび三環式尿素化合物
JPH10511980A (ja) * 1995-04-07 1998-11-17 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの阻害に有用な三環式化合物
JPH10511981A (ja) * 1995-04-07 1998-11-17 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の処置に有用な三環式化合物
WO1998057960A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523104A (ja) * 2004-12-13 2008-07-03 シェーリング コーポレイション 癌を治療するための新規なファルネシルタンパク質トランスフェラーゼ阻害剤およびその使用
JP2008523148A (ja) * 2004-12-14 2008-07-03 シェーリング コーポレイション ファルネシルプロテイントランスフェラーゼインヒビターおよび増殖性疾患を処置するための方法
JP2017512780A (ja) * 2014-03-19 2017-05-25 ヴィアメット ファーマスーティカルズ，インコーポレイテッド ２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−置換ピリジン−２−イル）−３−（１ｈ−テトラゾール−１−イル）プロパン−２−オールおよびその調製工程
US10301283B2 (en) 2014-03-19 2019-05-28 Dow Agrosciences, Llc 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation

Also Published As

Publication number Publication date
PL348293A1 (en) 2002-05-20
IL143408A0 (en) 2002-04-21
SK7592001A3 (en) 2002-03-05
ZA200104233B (en) 2002-08-22
NZ511878A (en) 2003-10-31
CZ20011950A3 (cs) 2001-12-12
KR20010081116A (ko) 2001-08-27
AR021718A1 (es) 2002-07-31
AU776558B2 (en) 2004-09-16
HUP0202152A2 (en) 2002-10-28
CA2354779A1 (en) 2000-06-29
WO2000037459A1 (en) 2000-06-29
TR200101755T2 (tr) 2001-09-21
EP1140902A1 (en) 2001-10-10
BR9916314A (pt) 2001-10-02
CN1326850C (zh) 2007-07-18
PE20001342A1 (es) 2000-12-09
CO5160350A1 (es) 2002-05-30
AU2030700A (en) 2000-07-12
NO20012961D0 (no) 2001-06-15
NO20012961L (no) 2001-08-16
CN1334811A (zh) 2002-02-06

Similar Documents

Publication Publication Date Title
US6372747B1 (en) Farnesyl protein transferase inhibitors
JP2999556B2 (ja) ファルネシルタンパク質トランスフェラーゼの阻害に有用な三環式化合物
US5721236A (en) Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
EP0819121B1 (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
AU699043B2 (en) Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6362188B1 (en) Farnesyl protein transferase inhibitors
US6075025A (en) Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
EP0815099A1 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
JP2002533335A (ja) ファルネシルタンパク質トランスフェラーゼインヒビター
EP0989983B1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
JP2002533336A (ja) 三環式ファルネシルタンパク質トランスフェラーゼインヒビター
WO1996031505A1 (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1998011106A1 (en) Tricyclic compounds useful as fpt inhibitors
US6071907A (en) Tricyclic compounds useful as FPT inhibitors
MXPA01006241A (en) Tricyclic farnesyl protein transferase inhibitors
SK33299A3 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase
HK1002865B (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
HK1002865A1 (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101206